Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1546-1556

  Ciardiello, Fortunato ^a   Caputo, Rosa ^a   Damiano, Vincenzo ^a   Caputo, Roberta ^a   Troiani, Teresa ^a   Vitagliano, Donatella ^a   Carlomagno, Francesca ^a   Veneziani, Bianca Maria ^a   Fontanini, Gabriella ^b   Bianco, A Raffaele ^a   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BLOOD VESSEL PERMEABILITY; BREAST; CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELL PROLIFERATION; COLON; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; OVARY; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH; TUMOR REGRESSION; TUMOR XENOGRAFT;

AGAR; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; NIH 3T3 CELLS; PACLITAXEL; PHOSPHORYLATION; PIPERIDINES; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 0037386774     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Folkman, J. Tumor angiogenesis. In: J. Mendelsohn, P. Howley, L. A. Liotta, and M. Israel (eds.), The Molecular Basis of Cancer, pp. 206-232. Philadelphia: W. B. Saunders, 1995.
2. Kerbel, R. S. Tumor angiogenesis: past, present, and the near future. Carcinogenesis (Lond.), 21: 505-515, 2000.
3. Ferrara, N., Houck, K., Jakeman, L., and Leung, D. W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev., 13: 18-32, 1992.
4. Ferrara, N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat., 36: 127-137, 1995.
5. Fontanini, G., Vignati, S., Boldrini, L., Chinè S., Silvestri, V., Lucchi, M., Mussi, A., Angeletti, C. A., and Bevilacqua, G. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin. Cancer Res., 3: 861-865, 1997.
6. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
7. Horak, E. R., Leek, R., Klenk, N., LeJeune, S., Smith, K., Stuart, N., Greenall, M., Stepniewska, K., and Harris, A. L. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastasis and survival in breast cancer. Lancet, 340: 1120-1124, 1992.
8. Fontanini, G., Lucchi, M., Vignati, S., Mussi, A., Ciardiello, F., De Laurentiis, M., De Placido, S., Basolo, F., Angeletti, C. A., and Bevilacqua, G. Angiogenesis as a prognostic indicator of survival in nonsmall-cell lung carcinoma: a prospective study. J. Natl. Cancer Inst. (Bethesda), 89: 881-886, 1997.
9. Goldman, C. K., Kim, J., Wong, W. L., King, V., Brock, T., and Gillespie, G. Y. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell, 4: 121-133, 1993.
10. Gille, J., Swerlick, R. A., and Caughman, S. W. Transforming growth factor alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP2-dependent DNA binding and transactivation. EMBO J., 16: 750-759, 1997.
11. Ciardiello, F., Damiano, V., Bianco, R., Bianco, C., Fontanini, G., De Laurentiis, M., De Placido, S., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst. (Bethesda), 88: 1770-1776, 1996.
12. Petit, A. M. V., Rak, J., Hung, M-C., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am. J. Pathol., 151: 1523-1530, 1997.
13. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., and Dinney, C. P. N. Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 5: 257-264, 1999.
14. Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G., De Placido, S., Bianco, A. R., Mendelsohn, J., and Tortora, G. Antiangiogenic and antitumor activity of antiepidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res., 6: 3739-3747, 2000.
15. Bruns, C. J., Solorzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R., Fan, D., Abbruzzese, J., Traxler, P., Buchdunger, E., Radinsky, R., and Fidler, I. J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res., 60: 2926-2935, 2000.
16. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., De Placido, S., Bianco, A. R., and Tortora, G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res., 7: 1459-1465, 2001.
17. Eatock, M. M., Scahtzlein, A., and Kaye, S. B. Tumor vasculature as a target for anticancer therapy. Cancer Treat. Rev., 26: 191-204, 2000.
18. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillet, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumor growth in vivo. Nature (Lond.), 362: 244-250, 1993.
19. Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., Krummen, L., Winkler, M., and Ferrara, N. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 57: 45934599, 1997.
20. Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.
21. Wedge, S. R., Ogilvie, D. J., Dukes, M., Kendrew, J., Curwen, J. O., Hennequin, L. F., Thomas, A. P., Stokes, S. E., Curry, B., Richmond, G. H. P., and Wadsworth, P. F. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res., 60: 970-975, 2000.
22. Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., Kiing, K., Overholser, J., Hooper, A., Pytowski, B., Witte, L., Bohlen, P., and Hicklin, D. J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res., 59: 5209-5218, 1999.
23. Brekken, R. A., Overholser, J. P., Stasmy, V. A., Waltenberg, J., Minna, J. D., and Thorpe, P. E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res., 60: 5117-5124, 2000.
24. Kunkel, P., Ulbricht, U., Bohlen, P., Brockmann, M. A., Fillbrandt, R., Stavrou, D., Westphal, M., and Lamszus, K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res., 61: 6624-6628, 2001.
25. Inoue, K., Slaton, J. W., Davis, D. W., Hicklin, D. J., McConkey, D. J., Karashima, T., Radinsky, R., and Dinney, C. P. N. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the antivascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin. Cancer Res., 6: 2635-2643, 2000.
26. Schlaeppi, J. M., and Wood, J. M. Targeting vascular endothelial growth factor (VEGF) for anticancer therapy, by anti-VEGF neutralizing monoclonal antibodies and VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev., 18: 473-481, 1999.
27. Cherrington, J. M., Strawn, L. M., and Shawver, L. K. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv. Cancer Res., 79: 1-38, 2000.
28. Hennequin, L. F., Thomas, A. P., Johnstone, C., Stokes, E. S. E., Ple, P. P., Wedge, S. R., Ogilvie, D. J., Kendrew, J., and Dukes, M. ZD6474: design, synthetic and structure activity relationship of a novel orally active VEGF receptor tyrosine kinase inhibitor. Proc. Am. Assoc. Cancer Res., 42: 3152, 2001.
29. Wedge, S. R., Ogilvie, D. J., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J. O., Musgrove, H. L., Graham, G. A., Hughes, G. D., Thomas, A. P., Stokes, E. S. E., Curry, B., Richmond, G. H. P., Wadsworth, P. F., Bigley, A. L., and Hennequin, L. F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res., 62: 4646-4655, 2002.
30. Wedge, S., Checkley, D., Tessier, J. J., Dukes, M., Kendrew, J., Curry, B. B., Middleton, B. B., and Waterton, J. C. Dynamic contrastenhance MRI study of human tumor xenografts treated with the VEGF signaling inhibitor ZD6474. Proc. Am. Assoc. Cancer Res., 42: 581, 2001.
31. Hrwitz, H. I., Eckardt, S. G., Holden, S. N., Basser, R., Deboer, R., Rosenthal, M., Rischin, D., Swaisland, H., Barge, A., McKinley, M., and Wheeler, C. A Phase I study of ZD6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumors. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2001.
32. Levitzki, A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther., 82: 231-239, 1999.
33. Levitt, M. L., and Koty, P. P. Tyrosine kinase inhibitors in preclinical development. Investig. New Drugs, 17: 213-226, 1999.
34. Ciardiello, F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs, 60: 25-32, 2000.
35. Ciardiello, F., and Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 7: 2958-2970, 2001.
36. Ciardiello, F., McGeady, M. L., Kim, N., Basolo, F., Hynes, N., Langton, B. C., Yokozaki, H., Saeki, T., Elliott, J. W., Masui, H., Mendelsohn, J., Soule, H., Russo, J., and Salomon, D. S. Transforming growth factor α expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene and overexpression of the transforming growth factor α complementary DNA leads to transformation. Cell Growth Differ., 1: 407-420, 1990.
37. Di Fiore, P. P., Pierce, J. H., Fleming, T. P., Hazan, R., Ullrich, A., King, C. R., Schlessinger, J., and Aaronson, S. A. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell, 51: 1063-1070, 1987.
38. Bianco, C., Tortora, G., Baldassarre, G., Caputo, R., Fontanini, G., Chinè, S., Bianco, A. R., and Ciardiello, F. 8-chloro-cAMP inhibits autocrine and angiogenic growth factors production in human colorectal and breast cancer. Clin. Cancer Res., 3: 439-448, 1997.
39. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., Bianco, A. R., and Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res., 6: 2053-2063, 2000.
40. Ciardiello, F., Bianco, R., Damiano, V., De Lorenzo, S., Pepe, S., De Placido, S., Fan, Z., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of sequential treatment with topotecan and antiepidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res., 5: 909-916, 1999.
41. Mendelsohn, J., and Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene, 19: 6550-6565, 2000.
42. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1992.
43. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. (Bethesda), 85: 1327-1333, 1993.
44. Bruns, C. J., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R., McConkey, D. J., Evans, D. B., Abbruzzese, J. L., Hicklin, D. J., and Radinsky, R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res., 6: 1936-1948, 2000.
45. Inoue, K., Slaton, J. W., Perrotte, P., Davis, D. W., Bruns, C. J., Hicklin, D. J., McConkey, D. J., Sweeney, P., Radinsky, R., and Dinney, C. P. N. Paclitaxel enhances the effects of the antiepidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res., 6: 4874-4884, 2000.
46. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., and Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res., 2: 1843-1849, 1996.
47. Gibbs, J. B. Anticancer drug targets: growth factors and growth factor signaling. J. Clin. Investig., 105: 9-13, 2000.
48. Inoue, K., Slaton, J. W., Davis, D. W., Bruns, C. J., Hicklin, D. J., McConkey, D. J., Karashima, T., Radinsky, R., and Dinney, C. P. N. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the antivascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin. Cancer Res., 6: 2635-2643, 2000.